Search

for
Search:

Sort by

Research

300-330 / 1000+ results

research Fixed, low radiant exposure vs. incremental radiant exposure approach for diode laser hair reduction: a randomized, split axilla, comparative single‐blinded trial

4 citations , August 2015 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

Both fixed and incremental laser treatments effectively reduced underarm hair, but the fixed method was less painful.

Efficacy and Safety of a Food Supplement Containing L-Cystine, Serenoa Repens Extract, and Biotin for Hair Loss in Healthy Males and Females: A Prospective, Randomized, Double-Blinded, Controlled Clinical Trial

research Efficacy and Safety of a Food Supplement Containing L-cystine, Serenoa repens Extract and Biotin for Hair Loss in Healthy Males and Females. A Prospective, Randomized, Double-blinded, Controlled Clinical Trial

3 citations , January 2017 in “Journal of cosmetology & trichology”

The food supplement with L-cystine, Serenoa repens extract, and biotin safely reduced hair loss and improved hair growth in men and women.

Comment on 'Effect of Pumpkin Seed Oil on Hair Growth in Men with Androgenetic Alopecia: A Randomized, Double-Blind, Placebo-Controlled Trial'

research Comment on “Effect of Pumpkin Seed Oil on Hair Growth in Men with Androgenetic Alopecia: A Randomized, Double-Blind, Placebo-Controlled Trial”

3 citations , January 2015 in “Evidence-based Complementary and Alternative Medicine”

Pumpkin seed oil may help hair growth, but more research needed on frontal hair loss and long-term effects.

research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial

2 citations , November 2025 in “Journal of the American Academy of Dermatology”

Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.

research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials

2 citations , September 2024 in “Journal of the American Academy of Dermatology”

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

research 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial

2 citations , September 2023 in “Journal of the American Academy of Dermatology”

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Evaluation of the Safety and Efficacy of Platelet-Rich Plasma in the Treatment of Female Patients with Chronic Telogen Effluvium: A Randomized, Controlled, Double-Blind, Pilot Clinical Trial

research Evaluation of the safety and efficacy of platelet-rich plasma in the treatment of female patients with chronic telogen effluvium: A randomised, controlled, double-blind, pilot clinical trial

2 citations , April 2022 in “Indian Journal of Dermatology, Venereology and Leprology”

Platelet-rich plasma is a promising and safe treatment for increasing hair density and thickness in women with chronic telogen effluvium.

research Efficacy, tolerability, and safety of montelukast versus finasteride for the treatment of moderate acne in women: A prospective, randomized, single‐blinded, active‐controlled trial

2 citations , October 2021 in “Journal of Cosmetic Dermatology”

Finasteride is more effective and satisfactory than montelukast for treating moderate acne in women.

Efficacy and Safety of Standardized Cinnamon Bark Extract for the Prevention of Chemotherapy-Induced Weight Loss and Alopecia in Patients with Breast Cancer: A Randomized, Double-Blind, and Placebo-Controlled Study

research EFFICACY AND SAFETY OF STANDARDIZED CINNAMON BARK EXTRACT FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED WEIGHT LOSS AND ALOPECIA IN PATIENTS WITH BREAST CANCER: A RANDOMIZED, DOUBLE-BLIND, AND PLACEBO-CONTROLLED STUDY

2 citations , August 2019 in “Asian journal of pharmaceutical and clinical research”

Cinnamon bark extract may help prevent weight loss and hair loss in breast cancer patients during chemotherapy and is safe to use.

research Blood pressure changes in patients after Minoxidil microinfusion to treat female pattern alopecia: analysis of a randomized, single blinded, placebo controlled clinical trial

1 citations , May 2025 in “Archives of Dermatological Research”

This study investigated the systemic effects of minoxidil microinfusion on blood pressure in 24 patients with female pattern alopecia. Participants were divided into two groups: one received 0.5% minoxidil, and the other received a saline solution as a control. Over three monthly sessions, blood pressure was measured before and after each procedure. Results showed a statistically significant reduction in diastolic blood pressure in the minoxidil group, indicating systemic absorption of the drug. Conversely, the control group experienced a significant increase in systolic blood pressure, likely due to pain from the procedure. This suggests that minoxidil microinfusion can affect blood pressure, highlighting the importance of monitoring systemic effects in such treatments.

research Effects of Withania somnifera root extract serum application on hair health in healthy adults: A prospective, double-blind, randomized, parallel, placebo-controlled study

1 citations , November 2023 in “Journal of Ayurveda and Integrative Medicine”

Ashwagandha serum improves hair health and quality of life in people with hair loss.

research Cervi Parvum Cornu complex for men with lower urinary tract symptoms: a multicenter, randomized, double-blind, placebo-controlled trial

1 citations , September 2023 in “Prostate International”

Cervi Parvum Cornu complex improved urinary symptoms in men without major side effects.

Safety and Efficacy of Orally Administered Cepharanthine in Non-Hospitalized, Asymptomatic or Mild COVID-19 Patients: A Double-Blind, Randomized, Placebo-Controlled Trial

research Safety and Efficacy of Oral administrated Cepharanthine in Non-hospitalized, asymptomatic or mild COVID-19 patients: A Double-blind, Randomized, Placebo-controlled Trial

1 citations , January 2023 in “bioRxiv (Cold Spring Harbor Laboratory)”

Cepharanthine is safe but not clearly effective in speeding up COVID-19 recovery.

research Correction to: The Effects of Lower vs Higher Cell Number of Platelet-Rich Plasma (PRP) on Hair Density and Diameter in Androgenetic Alopecia (AGA): A Randomized, Double-Blinded, Placebo, Parallel-Group Half-Scalp IRB-Approved Study

1 citations , September 2022 in “Aesthetic Surgery Journal”

Efficacy of Intramuscular Injections of Biotin and Dexpanthenol in the Treatment of Diffuse Hair Loss: A Randomized, Double-Blind Controlled Study Comparing Two Brands

research Efficacy of intramuscular injections of biotin and dexpanthenol in the treatment of diffuse hair loss: A randomized, double‐blind controlled study comparing two brands

1 citations , July 2022 in “Dermatologic Therapy”

Both brands of biotin and dexpanthenol injections improved hair loss, with Bayer also increasing the ratio of thick to thin hairs.

Efficacy and Safety of Topical Combination of 3% Minoxidil and 0.25% Finasteride Versus 3% Minoxidil Solution in Female-Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study

research Efficacy and safety of topical combination of 3% minoxidil and 0.25% finasteride versus 3% minoxidil solution in female-pattern hair loss: A randomized, double-blind, controlled study

1 citations , August 2018 in “Journal of The American Academy of Dermatology”

Combination of minoxidil and finasteride is more effective in increasing hair diameter than minoxidil alone for female-pattern hair loss.

A Proprietary Herbal Extract Against Hair Loss in Androgenetic Alopecia and Telogen Effluvium: A Placebo-Controlled, Single-Blind, Clinical-Instrumental Study

research A proprietary herbal extract against hair loss in androgenetic alopecia and telogen effluvium: a placebo-controlled, single-blind, clinical-instrumental study

1 citations , January 2018 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)”

The herbal extract was found to effectively reduce and prevent hair loss without any side effects.

The Beneficial Effects of an Oriental Herbal Complex Supplement on Women’s Hair and Scalp Conditions: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study

research The Beneficial Effects of an Oriental Herbal Complex Supplement on Women’s Hair and Scalp Conditions: A 24-week, Randomized, Double-blind, Placebo-controlled Study

1 citations , August 2017 in “Journal of food and nutrition research”

The herbal supplement increased hair thickness and reduced scalp oiliness in women.

Safety and Biopsy Outcomes of a Topical Treatment (SM04554) for Male Androgenetic Alopecia: Results from a Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Trial

research Safety and biopsy outcomes of a topical treatment (SM04554) for male androgenetic alopecia (AGA): Results from a phase 2, multicenter, randomized, double-blind, vehicle-controlled trial

1 citations , June 2017 in “Journal of The American Academy of Dermatology”

Topical treatment SM04554 safely promotes hair growth in male baldness.

research Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study.

1 citations , July 2016 in “PubMed”

Once-daily 5% minoxidil foam and twice-daily 2% minoxidil solution are similarly effective and safe for female pattern hair loss.

research Study of olive leaf extract on skin aging: Ex vivo, animal, and randomized double-blind placebo-controlled clinical studies

June 2026 in “Functional Foods in Health and Disease”

Olive leaf extract may help improve skin aging, especially for those who don't exercise regularly.

Efficacy, Safety, and Dose Response of STS01, a Topical Controlled Release Nanoparticle Formulation (Dithranol/Prosilic), in Adults with Mild to Moderate Patchy Alopecia Areata: A Randomized, Double-Blind, Multicenter, Phase 2 Trial

research Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial

April 2026 in “medRxiv”

STS01 1% effectively promotes hair regrowth with minimal side effects.

research Effectiveness of Single‐Wavelength 755 nm Laser Compared to Dual‐Wavelength 755 nm and 1064 nm Laser in Hair Removal: A Split‐Body Design With Blinding

March 2026 in “Health Science Reports”

The 755 nm laser is more effective and safer for hair removal than the dual-wavelength laser.

research A RANDOMIZED, PROSPECTIVE, SINGLE-BLIND CLINICAL TRIAL: COMPARATIVE STUDY OF COMPARING THE EFFICACY AND SAFETY OF DIFFERENT MINOXIDIL FORMULATIONS IN TREATING ANDROGENIC ALOPECIA

March 2026 in “Journal of medical & health sciences review.”

Both 5% minoxidil foam and liquid effectively treat hair loss, with foam slightly preferred.

Improvements in Scalp Elasticity and Hair Properties Following Supplementation with Low-Molecular-Weight Porcine Placental Peptides (Placenderm®): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

research Improvements in scalp elasticity and hair properties following supplementation with low-molecular-weight porcine placental peptides (Placenderm®): A randomized, double-blind, placebo-controlled clinical trial

February 2026

Placenderm® improves scalp elasticity and hair quality safely.

research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study

February 2026 in “Journal of Dermatological Treatment”

CG2001 is safe and well-tolerated for treating hair loss, with fewer side effects than oral finasteride.

Safety, Tolerability, and Pharmacokinetics of CG2001 in Chinese Adult Male Subjects With Androgenetic Alopecia: A Randomized, Double-Blind, Placebo-Controlled, Single- and Multi-Dose, Phase 1 Clinical Study

research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study

January 2026

CG2001 is safe, well-tolerated, and a promising treatment for hair loss with fewer side effects.

research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study

January 2026

CG2001 is safe and well-tolerated for treating hair loss in men.

research Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study

December 2025 in “Journal of Dermatological Treatment”

GT20029 helps regrow hair in men with hair loss and is well-tolerated.

Efficacy and Safety of a Drinkable Nutraceutical in Premenopausal Women with Telogen Effluvium: A 6-Month, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study

research Efficacy and Safety of a Drinkable Nutraceutical in Premenopausal Women with Telogen Effluvium: A 6-Month, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study

November 2025 in “Dermatology and Therapy”

The drinkable supplement increased hair growth and was safe for women with hair loss.

← Previous page Next page →